StockData
Puma Biotechnology, Inc. logo

Puma Biotechnology, Inc. (PBYI) stock

PBYINasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 14/3019% below fair value
$7.22+0.08 (+1.12%)

Close on Nov 18, 2026Market cap $372.70MP/E 13.9Yield –

Puma Biotechnology pe ratio

The price-to-earnings ratio is the share price divided by diluted earnings per share over the trailing twelve months.

Puma Biotechnology's pe ratio was 15.5× on Nov 11, 2026, against 6.8× a year earlier. Over the last 4 years it ranged from 4.0× to 58.8×, with a median of 11.8×.

PE Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026Nov 11, 202615.5×+7.5
2025Dec 31, 20258.0×+1.7
2024Dec 31, 20246.4×−47.8
2023Dec 29, 202354.1×+34.9
2022Dec 30, 202219.2×–

More Puma Biotechnology figures

See a number that looks wrong?